Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Assets (2016 - 2025)

Historic Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Assets fell 2261.61% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 2261.61%. This contributed to the annual value of $1.5 billion for FY2024, which is 83.45% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Assets stood at $1.2 billion, which was down 2261.61% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Assets registered a high of $1.6 billion during Q3 2022, and its lowest value of $1.2 billion during Q3 2025.
  • For the 5-year period, Ultragenyx Pharmaceutical's Assets averaged around $1.4 billion, with its median value being $1.5 billion (2021).
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 2956.87% in 2021, then plummeted by 2349.95% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Assets stood at $1.5 billion in 2021, then rose by 1.51% to $1.5 billion in 2022, then dropped by 3.52% to $1.5 billion in 2023, then grew by 0.83% to $1.5 billion in 2024, then dropped by 20.82% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.3 billion during Q1 2025.